SANTA CLARA, Calif. & BEIJING–Affymetrix Inc., (Nasdaq:AFFX) and CapitalBio Corporation, a leading life science company based in Beijing, P.R. China, announced that CapitalBio has become a certified Affymetrix Service Provider and will begin offering genotyping services using the Affymetrix GeneChip(R) Human Mapping 500K Array Set. The 500K Array enables researchers to search across the entire genome in detail to find genes involved in disease or drug response.

CapitalBio has been offering gene expression profiling services using Affymetrix microarray technology for more than a year. The two companies have also been working together on joint R&D and commercialization programs, including the development of an advanced GeneChip-compatible personal scanner.

“The gene expression and genotyping market are gaining momentum as more and more international pharmaceutical companies out-source microarray services in China and more and more Chinese scientists employ microarrays to solve biological problems,” said David Sun, senior vice president, Business Development and Marketing at CapitalBio. “As a Certified Affymetrix Service Provider, CapitalBio can now provide broader high quality microarray based services beyond its already extensive products and services to gain information at gene, protein, cell and tissue levels to address the increasing needs of global customers.”

About CapitalBio

CapitalBio is a leading life science Company that develops and commercializes a broad range of products, including Biochip technology products, for drug discovery research, genomics, proteomics, bio-safety testing and clinical applications. Headquartered in Beijing, China, CapitalBio has rapidly evolved from a young innovative biochip developer into a comprehensive life science entity with five affiliates or subsidiaries: AVIVA Biosciences, a San Diego, California based company that develops and markets on-chip patch-clamp technologies for ion-channel studies for drug discovery researches; Chipscreen Biosciences, a Biotech company located in Shenzhen, China, for small molecular drug discovery and development; and CapitalBio International and CapitalBio Hong Kong, two fully owned subsidiaries by CapitalBio Corporation, are based at San Diego, California and Hong Kong, China respectively. Additional information on CapitalBio can be found at www.capitalbio.com.